Welcome to our dedicated page for Merck & Co news (Ticker: MRK), a resource for investors and traders seeking the latest updates and insights on Merck & Co stock.
Merck & Co. (NYSE: MRK) is a global pharmaceutical leader with a 350-year legacy of medical innovation. This news hub provides investors and healthcare professionals with direct access to official announcements, financial disclosures, and research developments shaping the company's trajectory.
Track MRK's latest regulatory milestones, clinical trial results, and strategic partnerships through verified press releases and curated analysis. Our repository includes earnings call transcripts, FDA approval updates, and global health initiatives—all organized for efficient research and due diligence.
Key updates on therapeutic advancements in oncology, vaccines, and infectious diseases are maintained alongside financial performance data. Bookmark this page for real-time access to Merck's corporate communications and market-moving developments in the pharmaceutical sector.
Rhea-AI Summary
Merck announced significant results from the Phase 3 ASCENT-04/KEYNOTE-D19 study showing KEYTRUDA plus Trodelvy reduced disease progression or death risk by 35% compared to KEYTRUDA plus chemotherapy in first-line PD-L1+ metastatic triple-negative breast cancer (TNBC). The combination achieved median progression-free survival of 11.2 months versus 7.8 months with KEYTRUDA plus chemotherapy. The study demonstrated higher objective response rate (59.7% vs 53.2%) and longer duration of response (16.5 months vs 9.2 months) for KEYTRUDA plus Trodelvy. The safety profile was consistent with known profiles of both drugs, with no new safety signals identified. This marks the first pivotal Phase 3 trial showing superiority of KEYTRUDA plus a TROP2 antibody-drug conjugate versus standard care in first-line metastatic TNBC.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Merck announced promising Phase 1 KANDLELIT-001 trial results for MK-1084, their investigational KRAS G12C inhibitor, in treating advanced colorectal cancer (CRC) and non-small cell lung cancer (NSCLC) with KRAS G12C mutations. The drug showed encouraging antitumor activity both as monotherapy and in combinations. In CRC, MK-1084 demonstrated confirmed response rates of 38% as monotherapy, 46% when combined with cetuximab, and 38% with cetuximab plus chemotherapy. For NSCLC, response rates were 38% as monotherapy, notably 77% when combined with KEYTRUDA in untreated metastatic cases, and 53% with KEYTRUDA plus chemotherapy. The drug maintained a manageable safety profile across all treatment arms, with treatment-related adverse events ranging from 58% in monotherapy to 97% in combination therapies. Merck plans to advance MK-1084 to Phase 3 trials for both CRC and NSCLC treatments.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Merck announced promising results from the Phase 2/3 waveLINE-003 study of zilovertamab vedotin combined with R-GemOx for treating relapsed/refractory DLBCL. At the 1.75 mg/kg dose, the combination achieved a 56.3% objective response rate, including 8 complete responses and 1 partial response in 16 patients. The study evaluated three dose levels (1.5, 1.75, and 2.0 mg/kg), with 1.75 mg/kg selected as the recommended Phase 2 dose based on efficacy and safety data. Treatment-related adverse events occurred in 98% of patients, with Grade ≥3 events in 63%. The drug is currently being evaluated in multiple Phase 2 and 3 trials, including waveLINE-010, waveLINE-007, and waveLINE-011, for various DLBCL treatment settings.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Summary
Daiichi Sankyo and Merck (MRK) have voluntarily withdrawn their Biologics License Application (BLA) for patritumab deruxtecan (HER3-DXd) in the treatment of EGFR-mutated non-small cell lung cancer (NSCLC). The withdrawal follows topline overall survival results from the HERTHENA-Lung02 phase 3 trial that failed to meet statistical significance. While the trial showed statistically significant progression-free survival (PFS), the overall survival data did not reach the required threshold. The decision is unrelated to a previous Complete Response Letter from June 2024 regarding third-party manufacturing facility inspection findings. The companies will present detailed trial results at the 2025 ASCO Annual Meeting. The safety profile remained consistent with previous trials, with no new safety signals identified.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.3%
Tags
-
Rhea-AI Summary
Merck (NYSE: MRK) has announced its quarterly dividend payment for Q3 2025. The company's Board of Directors has declared a dividend of $0.81 per share of common stock. The dividend will be paid on July 8, 2025, to shareholders who are on record as of the close of business on June 16, 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.01%
Tags
-
Rhea-AI Summary
Merck (MRK) and Daiichi Sankyo have initiated the IDeate-Esophageal01 Phase 3 trial for ifinatamab deruxtecan (I-DXd), a potential first-in-class B7-H3 directed antibody drug conjugate. The trial will evaluate I-DXd versus standard chemotherapy in patients with advanced or metastatic esophageal squamous cell carcinoma (ESCC) who have progressed after platinum therapy and immunotherapy. ESCC represents 90% of global esophageal cancers with a dire 15-20% five-year survival rate. The trial's initiation follows promising results from the IDeate-PanTumor01 phase 1/2 trial presented at ESMO 2022 and 2023, which demonstrated encouraging responses in heavily pretreated ESCC patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.54%
Tags
Rhea-AI Summary
<p><b>Merck (MRK)</b> announced it will present new clinical and outcomes research data on <b>pulmonary arterial hypertension (PAH)</b> at the ATS 2025 International Conference in San Francisco. The company will showcase nine presentations, including a significant pooled analysis of WINREVAIR™ (sotatercept-csrk) from the PULSAR, SPECTRA, and STELLAR studies, along with the ongoing SOTERIA open-label extension study.</p><p>Key presentations will feature long-term safety data, overall survival analysis, and research on PAH's impact across various patient populations. The data represents the largest analysis of WINREVAIR to date, evaluating its safety, tolerability, and efficacy when combined with background therapy for PAH treatment.</p>
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.68%
Tags
-
Rhea-AI Summary
Merck (NYSE: MRK) announced positive results from its Phase 3 KEYNOTE-B96 trial evaluating KEYTRUDA (pembrolizumab) in combination with chemotherapy for platinum-resistant recurrent ovarian cancer. The trial met its primary endpoint of progression-free survival (PFS) in both PD-L1 expressing tumors and all comers. Significantly, the study achieved a secondary endpoint of overall survival (OS) in PD-L1 expressing tumors - marking the first time an immune checkpoint inhibitor-based regimen demonstrated an OS benefit in ovarian cancer. The KEYTRUDA-based treatment showed statistically significant improvements compared to placebo plus chemotherapy, with a safety profile consistent with previous studies. While KEYTRUDA is not yet approved for ovarian cancer treatment, these breakthrough results suggest potential new treatment options for this difficult-to-treat condition.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.81%
Tags
-
Rhea-AI Summary
The FDA has approved Merck's (MRK) WELIREG® (belzutifan) for treating adults and pediatric patients 12 years and older with locally advanced, unresectable, or metastatic pheochromocytoma or paraganglioma (PPGL). This marks WELIREG's third indication in the U.S. and establishes it as the only approved and available treatment for eligible PPGL patients. PPGL is a rare condition affecting up to 2,000 people annually in the U.S. The approval is based on the LITESPARK-015 clinical trial, which enrolled 72 patients. The drug targets hypoxia-inducible factor-2 alpha (HIF-2α) and is administered orally at 120 mg once daily. Important safety considerations include risks during pregnancy, potential for severe anemia requiring blood transfusion, and possible severe hypoxia requiring discontinuation, supplemental oxygen, or hospitalization.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.81%
Tags
Rhea-AI Summary
Merck (NYSE: MRK) will present extensive research from its oncology portfolio at the ASCO Annual Meeting (May 30-June 3, 2025), covering over 25 cancer types. Key highlights include first-time data for MK-1084, their KRAS G12C inhibitor, from the KANDLELIT-001 study in colorectal cancer and NSCLC. The company will showcase data on novel antibody-drug conjugates including zilovertamab vedotin and sacituzumab tirumotecan. Important updates include 5-year follow-up results for KEYTRUDA in renal cell carcinoma (KEYNOTE-564 trial) and WELIREG in VHL disease-associated tumors. Primary results from ASCENT-04/KEYNOTE-D19 trial evaluating KEYTRUDA plus sacituzumab govitecan-hziy in triple-negative breast cancer will be featured in ASCO's press program. Merck will host an Oncology Investor Event on June 2, 2025, to discuss their oncology strategy.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.72%
Tags
FAQ
What is the current stock price of Merck & Co (MRK)?
The current stock price of Merck & Co (MRK) is $76.84 as of May 30, 2025.
What is the market cap of Merck & Co (MRK)?
The market cap of Merck & Co (MRK) is approximately 195.5B.
Merck & Co
NYSE:MRK
MRK Rankings
MRK Stock Data
195.46B
2.51B
0.07%
80.45%
1.62%
Drug Manufacturers - General
Pharmaceutical Preparations
United States
RAHWAY